Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 4Dermatologic 4Breast 3Head & Neck 2Genitourinary 2Thoracic 1Plasma cell 1Lymphoid 1Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 10Melanoma 6Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Ovarian Neoplasms 3Carcinoma, Merkel Cell 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Squamous Cell 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma 1Liver Neoplasms 1Kidney Neoplasms 1Inflammatory Breast Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Chondrosarcoma 1

Interventions

pembrolizumab 10Gemcitabine 8Cyclophosphamide 7Filgrastim 5Docetaxel 5Carboplatin 5Trastuzumab 4Surveys and Questionnaires 4Nivolumab 4Doxorubicin 4Cisplatin 4poly ICLC 3pazopanib 3atezolizumab 3aldesleukin 3Taxes 3Radiotherapy 3Paclitaxel 3Oncolytic Virotherapy 3Irinotecan 3Ipilimumab 3Injections 3Drug Therapy 3Cetuximab 3Capecitabine 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3spartalizumab 2palbociclib 2liposomal doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Sarcoma × poly ICLC × Breast × Clear all
NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

University of Southern California

Phase 1 Active not recruiting
14 enrolled
BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ludwig Institute for Cancer Research

Phase 1/2 Completed
58 enrolled 24 charts
BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡